CRBP
Income statement / Annual
Last year (2023), Corbus Pharmaceuticals Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Corbus Pharmaceuticals Holdings, Inc.'s net income was -$44.60 M.
See Corbus Pharmaceuticals Holdings, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$881,705.00
|
$3.94 M
|
$36.14 M
|
$4.82 M
|
$2.44 M
|
$1.91 M
|
$648,382.00
|
$0.00
|
| Cost of Revenue |
$31.17 M |
$1.49 M |
$1.64 M |
$98,267.00 |
$89,604.00 |
$48.61 M |
$26.04 M |
$15.44 M |
$5.89 M |
$1.26 M |
| Gross Profit |
-$31.17 M |
-$1.49 M |
-$757,527.00 |
$3.84 M |
$36.05 M |
-$43.79 M |
-$23.60 M |
-$13.53 M |
-$5.24 M |
-$1.26 M |
| Gross Profit Ratio |
0 |
0 |
-0.86 |
0.98 |
1 |
-9.08 |
-9.67 |
-7.08 |
-8.08 |
0 |
| Research and Development
Expenses |
$31.17 M
|
$16.14 M
|
$36.45 M
|
$98.27 M
|
$89.60 M
|
$48.61 M
|
$26.04 M
|
$15.44 M
|
$5.89 M
|
$1.26 M
|
| General & Administrative
Expenses |
$13.91 M
|
$18.70 M
|
$20.43 M
|
$28.48 M
|
$23.64 M
|
$12.96 M
|
$8.96 M
|
$6.46 M
|
$3.61 M
|
$1.39 M
|
| Selling & Marketing
Expenses |
-$641,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.27 M
|
$18.70 M
|
$20.43 M
|
$28.48 M
|
$23.64 M
|
$12.96 M
|
$8.96 M
|
$6.46 M
|
$3.61 M
|
$1.39 M
|
| Other Expenses |
-$30.53 M |
-$48,773.00 |
$11.90 M |
$13.27 M |
$4.58 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$13.91 M |
$34.84 M |
$56.87 M |
$126.75 M |
$113.25 M |
$61.57 M |
$35.00 M |
$21.90 M |
$9.50 M |
$2.65 M |
| Cost And Expenses |
$45.08 M |
$34.84 M |
$56.87 M |
$126.75 M |
$113.25 M |
$61.57 M |
$35.00 M |
$21.90 M |
$9.50 M |
$2.65 M |
| Interest Income |
$0.00 |
$0.00 |
$1,830.49 |
$1,028.36 |
$1.23 M |
$982,777.00 |
$183,112.00 |
$477.00 |
$3,417.00 |
$2,115.00 |
| Interest Expense |
$2.92 M |
$2.13 M |
$1.83 M |
$1.03 M |
$19,025.00 |
$0.00 |
$183,112.00 |
$0.00 |
$2,440.00 |
$24,021.00 |
| Depreciation &
Amortization |
$640,601.00
|
$1.49 M
|
$1.64 M
|
$1.69 M
|
$1.23 M
|
$493,938.00
|
$255,652.00
|
$87,664.00
|
$43,943.00
|
$10,405.00
|
| EBITDA |
-$44.44 M
|
-$38.73 M
|
-$54.97 M
|
-$121.69 M
|
-$76.37 M
|
-$56.25 M
|
-$32.31 M
|
-$19.90 M
|
-$8.81 M
|
-$2.64 M
|
| EBITDA Ratio |
0 |
0 |
-63.82 |
-31.01 |
-2.13 |
-11.79 |
-13.33 |
-10.4 |
-13.58 |
0 |
| Operating Income Ratio
|
0
|
0
|
-63.5
|
-31.19
|
-2.13
|
-11.77
|
-13.34
|
-10.46
|
-13.66
|
0
|
| Total Other
Income/Expenses Net |
$473,985.00
|
-$2.51 M
|
$10.35 M
|
$11.54 M
|
$5.65 M
|
$1.08 M
|
$141,204.00
|
-$13,617.00
|
$2,954.00
|
$106,688.00
|
| Income Before Tax |
-$44.60 M |
-$42.35 M |
-$45.64 M |
-$111.27 M |
-$71.45 M |
-$55.67 M |
-$32.42 M |
-$20.00 M |
-$8.85 M |
-$2.54 M |
| Income Before Tax Ratio
|
0
|
0
|
-51.76
|
-28.26
|
-1.98
|
-11.54
|
-13.29
|
-10.46
|
-13.65
|
0
|
| Income Tax Expense |
$0.00 |
$13.49 M |
-$87,838.00 |
$35,046.00 |
-$2.30 M |
$1.08 M |
-$396,856.00 |
$13,617.00 |
$2,440.00 |
$24,021.00 |
| Net Income |
-$44.60 M |
-$55.83 M |
-$45.55 M |
-$111.30 M |
-$69.15 M |
-$55.67 M |
-$32.42 M |
-$20.00 M |
-$8.85 M |
-$2.54 M |
| Net Income Ratio |
0 |
0 |
-51.66 |
-28.27 |
-1.91 |
-11.54 |
-13.29 |
-10.46 |
-13.65 |
0 |
| EPS |
-10.31 |
-13.39 |
-11.11 |
-42.74 |
-32.47 |
-29.3 |
-19.38 |
-14.58 |
-8.47 |
-3.78 |
| EPS Diluted |
-10.31 |
-13.39 |
-11.11 |
-42.74 |
-32.47 |
-29.3 |
-19.38 |
-14.58 |
-8.47 |
-3.78 |
| Weighted Average Shares
Out |
$4.33 M
|
$4.17 M
|
$4.10 M
|
$2.60 M
|
$2.13 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.05 M
|
$671,995.00
|
| Weighted Average Shares
Out Diluted |
$4.33 M
|
$4.17 M
|
$4.10 M
|
$2.60 M
|
$2.13 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.05 M
|
$671,995.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
